---
title: "GLP-1 Drugs May Help Reduce Lung Scarring After COVID"
id: "medical-news-today-0-how-glp-1-drugs-like-ozempic-could-help-prevent-lung-scarring-after-covid"
canonical_url: "https://medichelpline.com/clinical-feed/medical-news-today-0-how-glp-1-drugs-like-ozempic-could-help-prevent-lung-scarring-after-covid"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "Medical News Today"
source_url: "https://www.medicalnewstoday.com/articles/how-glp-1-drugs-ozempic-could-help-prevent-lung-scarring-after-covid-diabetes/"
published_at: "2026-07-12T11:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 Drugs May Help Reduce Lung Scarring After COVID
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medical-news-today-0-how-glp-1-drugs-like-ozempic-could-help-prevent-lung-scarring-after-covid
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** Medical News Today
- **Source URL:** [Original Journal Publication](https://www.medicalnewstoday.com/articles/how-glp-1-drugs-ozempic-could-help-prevent-lung-scarring-after-covid-diabetes/)
- **Published At:** 2026-07-12T11:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
Researchers from the University of Hong Kong investigated why people with type 2 diabetes are more likely to experience respiratory complications after COVID-19 and what can be done to prevent this. They discovered that inflammatory immune cells may contribute to lung scarring after a SARS-CoV-2 infection and that GLP-1 medications may offer protection. According to the Centers for Disease Control and Prevention (CDC), about 1 in 8 people in the U.S. has diabetes, and type 2 diabetes makes up more than 90% of cases. Doctors prescribe GLP-1 receptor agonists, including semaglutide and tirzepatide , to treat type 2 diabetes and obesity. Besides improving blood sugar control and promoting weight loss, these drugs may also reduce the risk of cardiovascular and kidney disease. People with type 2 diabetes have a higher risk of developing long COVID and pulmonary fibrosis, a condition where scar tissue builds up in the lungs and makes breathing more difficult.
## Clinical Analysis & Structured Key Points
Medical News Today published a clinical update in Research Highlights on 12 Jul 2026. The item focuses on How GLP-1 drugs like Ozempic could help prevent lung scarring after COVID. Review the original article for the full source wording and details.
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Orforglipron Added to Titrated Insulin Glargine Improves Glycemic Control and Weight in Type 2 Dia](https://medichelpline.com/clinical-feed/pubmed-42251769.md) (DOI: 10.1001/jama.2026.9512)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.